	US 12,257,283 B2
	Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
Michael R. Ruff, Potomac, MD (US)
Assigned to Creative Bio-Peptides, Inc., Potomac, MD (US)
Filed by Creative Bio-Peptides, Inc., Potomac, MD (US)
Filed on Aug. 25, 2022, as Appl. No. 17/822,217.
Application 17/822,217 is a division of application No. 17/129,837, filed on Dec. 21, 2020, granted, now 11,510,961.
Claims priority of provisional application 62/950,776, filed on Dec. 19, 2019.
Prior Publication US 2023/0062853 A1, Mar. 2, 2023
Int. Cl. A61K 38/08 (2019.01); A61P 25/30 (2006.01); A61P 25/36 (2006.01)

CPC A61K 38/08 (2013.01) [A61P 25/30 (2018.01); A61P 25/36 (2018.01)]

13 Claims

1. A method of treating a patient with a substance abuse disorder wherein the substance abuse disorder is selected from the group consisting of: an amphetamine-type abuse, a MDMA (3,4-methylenedioxy-N-methylamphetamine) abuse, and a substance for attention-deficit hyperactivity disorder treatment abuse, the method comprising:

administering to the patient a therapeutically effective dose of a pharmaceutical composition that comprises:

(i) a chemokine receptor antagonist that comprises five contiguous amino acids having the general structure: A-B-C-D-E in which:

A is Ser, Thr, Asn, Glu, or Ile,

B is Ser, Thr, Asp, or Asn,

C is Thr, Ser, Asn, Arg, or Trp,

D is Tyr,

E is Thr, Ser, Arg, or Gly, wherein all stereoisomeric amino acids in A-B-C-D-E are in the D configuration,

or the chemokine receptor antagonist that comprises Dala₁-peptide T-amide (dASTTNYT-NH₂), and

(ii) a pharmaceutically acceptable carrier,

wherein the administering of the therapeutically effective dose results in a reduction of a symptom associated with the substance abuse disorder, as compared to the patient before the administering, thereby treating the substance abuse disorder.